Morning Read: Gilead must pay Merck $200M for patent infringement

Also, J. Craig Venter’s crew has lab-engineered a species of bacteria out of the minimum level of genetic code.

biotech investing JP Morgan 2016


Gilead has been ordered to pay Merck $200 million for infringing on two patents related to its hepatitis C drug goldmine – namely, Solvaldi and Harvoni. This is a fairly easy out for Gilead – Merck wanted $2 billion initially. –New York Times

J. Craig Venter’s crew has lab-engineered a species of bacteria out of the minimum level of genetic code – creating the most genetically efficient form of life that we know. It’s been a two decade process to create this new microbe, which is made up of 473 genes. –Forbes


We may see some restructuring at Forum Pharmaceuticals: Two studies for schizophrenia drugs failed in late stage trials – Xconomy

Bayer is looking to stay in the eye drug space, and is committing $130 million to Regeneron to develop a next-gen version of its Eylea drug. –Fierce Biotech


How did circulating fetal DNA research come to fruition? Here’s the path taken by Hong Kong geneticist Yuk Ming Dennis Lo. –CNN


Looks like a preventative model for diabetes care can actually work out, or so says Health and Human Services Secretary Sylvia Burwell. A YMCA diabetes prevention program is the first time a CMS Innovation Center preventative service has become eligible for expansion in Medicare. –Healthcare IT News


Health sensor startup LifeBeam just raised $16 million to launch  direct-to-consumer wearable. –MobiHealthNews

Health and Human Services has created a new, 21-member cybersecurity task force to respond to the increasing number of cyber attacks on health information systems. –Healthcare Dive

In a new blog from the luminaries behind the Precision Medicine Initiative, we learn that its Sync 4 Science pilot program won’t define the standards of interoperability – but will build on community efforts in the space. –HealthIT Buzz


The Congressional Budget Office let loose the latest numbers on projected ObamaCare performance and the results are mixed. Federal health insurance subsidies are up 11 percent to $660 billion, whereas enrollment will be slightly down. –The Hill


In this era of pathogen paranoia, here are five mysterious diseases you may not know anything about. –Time